The role of photocoagulation in retinal vein occlusion (RVO) has been studied since 1974.
The most serious complications of central retinal vein occlusion (CRVO) and branch retinal …

Diabetic retinopathy remains the most common complication of diabetes mellitus and is a
leading cause of visual loss in industrialized nations. The clinicopathology of the diabetic …

PURPOSE: Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5
mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO) …

Purpose To determine whether scatter and grid laser photocoagulation (laser) adds benefit
to ranibizumab injections in patients with macular edema from retinal vein occlusion (RVO) …

Background Central retinal vein occlusion (CRVO) is a relatively common retinal vascular
disorder in which macular oedema may develop, with a consequent reduction in visual …

Macular edema is the pathological accumulation of fluid in the central retina. It is a
complication of many retinal diseases, including diabetic retinopathy, retinal vascular …

Objective To compare pro re nata (PRN) and monthly injections of 0.5 mg ranibizumab in
retinal vein occlusion (RVO) patients stabilized by monthly injections. Design Randomized …

Purpose To assess the efficacy of intravitreal 0.5 mg ranibizumab for the treatment of center-
involving macular edema secondary to branch retinal vein occlusion (BRVO) over 1 year …

Purpose To determine the percentage of ranibizumab-treated patients with retinal vein
occlusion (RVO) who had resolution of edema for at least 6 months after the last injection …

Anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to be effective
at improving vision in patients with macular oedema due to diabetic retinopathy and vein …